Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Approval based on pivotal CABINET Phase III trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors, respectively3,4
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
15 hours ago
- Cision Canada
Pendopharm® signs an exclusive distribution agreement with Neuraxpharm for PrBuccolam® in Canada and announces its approval by Health Canada Français
MONTREAL, Aug. 4, 2025 /CNW/ - Pendopharm, a division of Pharmascience Inc., is pleased to announce that it has entered into an exclusive distribution agreement with Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, headquartered in Düsseldorf, Germany. Under the terms of the agreement, Pendopharm ® will be responsible for the commercialization of Buccolam ® (Midazolam Hydrochloride Oromucosal Solution) in Canada. Buccolam ® is indicated for the treatment of prolonged, acute, convulsive seizures in children. Pendopharm ® is pleased to announce that Health Canada has approved Buccolam ®. About Epilepsy Epilepsy is a chronic neurological disorder characterized by recurrent seizures of various types and severity. These seizures result from abnormal electrical activity in the brain and can be triggered by a range of factors, including structural abnormalities, brain inflammation, physical injury, trauma, infection, or unknown causes. It is estimated that the underlying cause of epilepsy remains undetermined in up to 50% of patients diagnosed with epilepsy. 1 Nearly 1 out of 100 Canadians live with epilepsy, and approximately 13% of them are children and youth. 1 Despite treatment with anti-seizure medications, some patients may experience prolonged acute convulsive seizures which require immediate intervention. Early treatment of acute seizures is critical to prevent escalation and improve patient outcomes. 2,3 Benzodiazepines, are considered first-line therapy for managing prolonged seizures. 4 Buccolam ® is an oromucosal solution of midazolam (a benzodiazepine) supplied in a ready-to-use, pre-filled syringes for buccal (absorbed in the mouth) administration. 5 "Prolonged convulsive seizures in pediatric patients can have significant short- and long-term impacts", said Dr. Aris Hadjinicolaou, Pediatric Neurologist at CHU Sainte-Justine. "Having access to a ready-to-use, on-label medication could facilitate timely intervention during seizures and may decrease the need for emergency medical services". " This partnership represents Pendopharm's commitment to bringing medicines that address unmet medical needs to Canadian patients," said Jad Isber, Vice President & General Manager of Pendopharm ®. "We look forward to working with Canadian neurologists and pediatricians to make Buccolam available to all patients who may benefit from it." Dr. Maximilian von Wülfing, Chief Operating Officer of Neuraxpharm, said: "Through its network of strategic partnerships around the world, Neuraxpharm is committed to expanding access to market-leading medicines. Our collaboration with Pendopharm further strengthens our position as a global CNS specialist enabling us to deliver an epilepsy treatment designed to reduce hospitalizations and provide support to patients and their caregivers." About Pendopharm ® Pendopharm, specialty division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company providing patients with innovative medicines that address unmet medical needs. Its areas of focus are gastroenterology, sports medicine & orthopedics, neurology and cardiology. Pendopharm ® has extensive experience and knowledge to successfully manage its growing product portfolio. For more information, please visit For media inquiries, please contact [email protected]. © 2025 Pendopharm, division of Pharmascience Inc. All rights reserved. About Pharmascience Inc. Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada and is headquartered in Montreal, Canada. Pharmascience delivers high-quality medicines to over 50 countries worldwide. Pharmascience Inc.'s global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients' needs. About the Neuraxpharm Group Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 40 years. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships and acquisitions. The company has c.1,000 employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, one in Australia, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. For more information, please visit .
Toronto Star
4 days ago
- Toronto Star
EU chief's texts to a pharma boss during pandemic were likely erased, the NYT reports
BRUSSELS (AP) — Text messages exchanged between European Commission President Ursula von der Leyen and a pharmaceutical boss during the COVID-19 pandemic were seen by her top adviser and have likely been destroyed, the New York Times reported Friday. Von der Leyen and Pfizer CEO Albert Bourla exchanged the messages as COVID-19 ravaged European communities from Portugal to Finland and the EU scrambled to buy millions of hard to find vaccines. She was under intense scrutiny to deliver.
Toronto Star
5 days ago
- Toronto Star
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology H1 core operating income of €656m, growing by 21.9% as reported, with a core operating margin of 36.0% of total sales, increasing by 3.6 points Upgraded FY 2025 financial guidance2: total-sales growth greater than 7.0% at CER (prior guidance: greater than 5.0% at CER); core operating margin greater than 32.0% of total sales (prior guidance: greater than 30%) Pipeline progression including regulatory filing of tovorafenib in Europe, and initiation of a Phase II trial of LANT3 (IPN10200) in cervical dystonia European Commission approval on 23 July 2025 of Cabometyx® in advanced neuroendocrine tumors (NETs), the sixth indication Key upcoming milestones with the pivotal FALKON trial results for fidrisertib in FOP4 and the Proof-of-Concept data readout for the LANT in aesthetics
